207 results
6-K
EX-99.1
SNY
Sanofi
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
and help alleviate the strain RSV disease places on babies, families, and health care systems.”
The provisional ACIP recommendations will be forwarded
6-K
EX-99.4
SNY
Sanofi
20 Jun 23
Current report (foreign)
10:18am
agreed between Sanofi and BI as part of the January 2017 swap of Sanofi’s Animal Health business for BI’s Consumer Health Care business
6-K
EX-99.2
SNY
Sanofi
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
to influence the critical need to address health care disparities globally. With my experience in leading global DE&I transformations I am motivated
6-K
EX-99.1
SNY
Sanofi
4 Apr 22
Distribution of Shares of Euroapi
11:21am
, for third-party payers such as government programs or public and private insurance plans and health care networks, to provide coverage and reimbursement … by the authorities, particularly for generic products, related to efforts by governments to limit health care and reimbursement costs. For example
6-K
EX-99.1
bzf49ezixbmgbui
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
6-K
EX-99.1
j7aghkocuk3v06kgzp
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
SC TO-T
EX-99
prml70hya2051k4yf
16 Aug 21
Third party tender offer statement
8:09am
6-K
EX-99.1
40dyv4pj8
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am
SC TO-T
EX-99
aeyitfehcm6ag8 a0q11
28 Aug 20
Third party tender offer statement
6:24am
6-K
EX-99.2
7ex 82do15
27 Apr 20
Current report (foreign)
4:39pm
SC TO-T
EX-99
14mhvzgzuohc4k lt
27 Dec 19
Third party tender offer statement
5:27pm
6-K
EX-99.2
868box3b8 7ttehao
7 Jan 19
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
9:07am
424B5
byvjv c78wb0c665
12 Jun 18
Prospectus supplement for primary offering
8:30am